| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | serdemetan | FIMM | pan-cancer | AAC | 0.037 | 0.9 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.0078 | 0.9 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | Imatinib | FIMM | pan-cancer | AAC | 0.039 | 0.9 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |